Pitt Street Research | Stock research
Atriva Therapeutics.jpg

Atriva Therapeutics

Atriva Therapeutics is a privately-held host-cell targeting antiviral drug developer based in Munich, Germany. The company's lead candidate is zapnometinib, a small molecule, which has been studied in Phase 2 in patients hospitalised with severe Covid-19 and which will enter a Phase 2 clinical development program in in 2024 in severe influenza.

Atriva Therapeutics has raised more than EUR40m in capital since its 2015 founding, with backing from venture capital, the European Investment Bank and the German government. It has good prospects given the need for new antivirals in influenza as part of pandemic preparedness measures globally.

Atriva Therapeutics

 

Atriva Therapeutics is a privately-held host-cell targeting antiviral drug developer based in Munich, Germany. The company's lead candidate is zapnometinib, a small molecule, which has been studied in Phase 2 in patients hospitalised with severe Covid-19 and which will enter a Phase 2 clinical development program in in 2024 in severe influenza.

The company has raised more than EUR40m in capital since its 2015 founding, with backing from venture capital, the European Investment Bank and the German government. It has good prospects given the need for new antivirals in influenza as part of pandemic preparedness measures globally.

9 November 2023

We spoke with Christian Pangratz, CEO of Atriva Therapeutics, about the current transaction, which will see the company going public on the Canadian Securities Exchange via a reverse take-over of BioCure Technology (CSE: CURE).